NCT00716651View on ClinicalTrials.gov

Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome

PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

July 31, 2010

Conditions

Churg Strauss Syndrome

Interventions

DRUG

mepolizumab

750 mg mepolizumab iv q4wk until week 32

Trial Locations (1)

24576

University Hospital Schleswig Holstein, Rheumaklinik Bad Bramstetd, Bad Bramstedt

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

University Hospital Schleswig-Holstein

OTHER

NCT00716651 - Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome | Biotech Hunter | Biotech Hunter